linjc16/ctgov huggingface dataset:
Peritoneal Carcinomatosis Extent Evaluation: Radiologic, Laparoscopic and Pathologic.

Study Overview
=================
Brief Summary
-----------------
pathologically proved ovarian cancer patients that underwent contrast enhanced abdomino-pelvic CT and diagnostic laparoscopy before cytoreductive surgery (CRS) will be included in the study. Calculation of PCI (peritoneal cancer index) using Sugarbaker's method, peritoneal carcinomatosis extent will be categorized into low, moderate and large. Agreement in general and in each category between CT, laparoscopy, surgery and pathology will be assessed using kappa agreement.

Detailed Description
-----------------
we will search medical records of primary ovarian cancer patients underwent CT abdomen, laparoscopy followed by cytoreductive surgery to calculate peritoneal carcinomatosis extent by each modality. Regional PCI was calculated in each of the 13 anatomical abdominopelvic regions, then total PCI by summation of the lesion size score, it ranged from 0 to 39. Categorization of peritoneal carcinomatosis was classified into 3 categories low if PCI < 10, moderate if 10-20, and large if >20.

Official Title
-----------------
Imaging Evaluation of Peritoneal Carcinomatosis Extent

Conditions
-----------------
Peritoneal Carcinomatosis

Intervention / Treatment
-----------------
* Diagnostic Test: laparoscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:pathologically proved ovarian cancer patients underwent contrast enhanced abdominopelvic CT and diagnostic laparoscopy before cytoreductive surgery - Exclusion Criteria:recurrent ovarian cancer -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: laparoscopy|evaluation of peritoneal carcinomatosis by laparoscopy|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| peritoneal carcinomatosis | Agreement in general and in each category between CT, laparoscopy, surgery and pathology was assessed using kappa agreement. | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| surgical decision making. | correlation of peritoneal carcinomatosis categorization with surgical decision | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ovarian Neoplasms, Laparoscopy, Cytoreduction Surgical Procedures.
Investigation of Genetic Disease Marker Associated With Korean Glaucoma Patients

Study Overview
=================
Brief Summary
-----------------
A single-nucleotide polymorphism (SNP) analysis of DNA obtained from peripheral blood of the glaucoma patients and the normal control will be performed to find genetic marker for primary open angle glaucoma.

Detailed Description
-----------------
Unrelated Korean subjects who have primary open angle glaucoma were recruited in the current study. Genotyping for various SNP associated with POAG due to the linkage disequilibrium patterns is to be performed. Genotypes would be statistically compared between patients with primary open angle glaucoma and normal control subjects free of any eye diseases.

Official Title
-----------------
Investigation of Genetic Disease Marker Associated With Korean Glaucoma Patients Patients, A Single-nucleotide Polymorphism(SNP)Analysis for Primary Open Angle Glaucoma

Conditions
-----------------
Single-nucleotide Polymorphism (SNP) for Glaucoma

Intervention / Treatment
-----------------
* Genetic: SNP analysis of the DNA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of primary open angle glaucoma Exclusion Criteria: Primary open angle glaucoma combined with congenital ocular disease Primary open angel glaucoma combined with other ocular disease Significant systemic disease other than systemic hypertension and diabetes

Ages Eligible for Study
-----------------
Minimum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| POAG group<br>Elevated intraocular pressure normal open angle glaucomatous optic nerve head abnormality glaucomatous visual field defect | Genetic: SNP analysis of the DNA<br>* SNP analysis of the DNA obtained from peripheral blood sample<br>|
| Normal control<br>Normal intraocular pressure No optic disc abnormality No visual field defect No significant ocular and systemic disease | Genetic: SNP analysis of the DNA<br>* SNP analysis of the DNA obtained from peripheral blood sample<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| genotyping for the SNP associated with primary open angle glaucoma |  | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| genotyping for rs7961953 and additional SNPs in TMTC2 from other linkage disequilibrium patterns |  | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
SNP, single-nucleotide polymorphism, glaucoma, primary open angle glaucoma
Use of the SWAMECO Questionnaire Basel

Study Overview
=================
Brief Summary
-----------------
A patient self-report questionnaire was developed that assesses subjective swallowing difficulties with medication intake, the SWAMECO questionnaire. It was validated in a highly specific population and will now be tested in the general population.

Detailed Description
-----------------
Based on a systematic literature review, a novel self-report questionnaire was developed in 2016 to assess subjective swallowing difficulties with medication intake and their practical consequences in ambulatory patients, the SWAMECO questionnaire. It consists of 30 items divided into 5 sections Complaints, Intensity, Localization, Coping strategies, and Adherence to medication. It was validated in people suffering from systemic sclerosis (SSc), a rare multisystem autoimmune disease that often leads to swallowing problems with food and liquids with progression. The aim of this study is now to validate the questionnaire in the general population. Patients presenting in the community pharmacy with a prescription of at least 3 different medications for a minimum of 3 months will fill in the questionnaire on site.

Official Title
-----------------
Use of the SWAMECO Questionnaire in the General Population to Detect Swallowing Difficulties

Conditions
-----------------
Swallowing Difficulties

Intervention / Treatment
-----------------
* Other: Self-report questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: aged 18 years or more is living in the community setting is receiving three or more medications for a period not less than three months, independently of the frequency of the intake Exclusion Criteria: patients who are not able to provide written conformed consent will be excluded

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Self-report questionnaire|Fill in the SWAMECO questionnaire|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| swallowing difficulties assessed by Questionnaire | The variable of primary interest is the answer to the question number 4: Do you experience swallowing difficulties when you take your medicines? | 5 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| medication adherence assessed by Questionnaire | Answers to q 26-28: how many days did you miss at least one dose of any of your medicines?, how good a job did you do at taking your medicines in the way you were supposed to?, how often did you take your medicines in the way you were supposed to? | 5 minutes |
Pain Using Reduced Fluence Parameters in Photocoagulation for Diabetic Retinopathy.

Study Overview
=================
Brief Summary
-----------------
The used of reduced fluence parameters for panretinal photocoagulation decreases pain as perceived by the patient, compared to traditional parameters.

Official Title
-----------------
Pain Using Reduced Fluence Parameters in Photocoagulation for Diabetic Retinopathy.

Conditions
-----------------
Proliferative Diabetic Retinopathy

Intervention / Treatment
-----------------
* Procedure: Retinal laser photocoagulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients 18 years or older, that signed informed consent Proliferative diabetic retinopathy with indication for panretinal photocoagulation Exclusion Criteria: Previous retinal photocoagulation Previous ocular surgical procedures Ocular media opacities History of trigeminal neuralgia Chronic ocular pain Depression under conductual or medical treatment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Reduced Fluence Parameters<br>Eyes receiving retinal photocoagulation with reduced fluence parameters (time 20-50 msec, power 400-700 mW) | Procedure: Retinal laser photocoagulation<br>* Retinal laser photocoagulation using a 532 nm laser<br>* Other names: Alcon Eyelite 532 (doubled frequency Nd:Yag);|
| Active Comparator: Traditional parameters<br>Eyes receiving retinal photocoagulation with traditional parameters (time 100-200 msec, power 200-400 mW) | Procedure: Retinal laser photocoagulation<br>* Retinal laser photocoagulation using a 532 nm laser<br>* Other names: Alcon Eyelite 532 (doubled frequency Nd:Yag);|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain (NRS-11 scale) |  | Immediately post-treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Proliferative diabetic retinopathy, Laser photocoagulation, Pain
Mhealth Supported Bundle to Improve Vaccination Completion

Study Overview
=================
Brief Summary
-----------------
Supported be a digital vaccine registry the investigators will test the impact of automated appointment reminders, real time appointment reminders, motivational interviewing and targeted vaccine on routine childhood vaccine completion rates.

Detailed Description
-----------------
Bundling three high-impact mHealth interventions (a digital vaccine registry (supply side), a reminder system (demand side), and targeted vaccine drive (demand and supply-side) will be feasible, acceptable, carried out with fidelity, and result in a 10% improvement in vaccine completion rates compared to the year prior to implementation.

Official Title
-----------------
Implementing a Mobile Health Supported Bundle to Improve Routine Vaccination Completion Rate in a Low-resource Setting

Conditions
-----------------
Vaccination

Intervention / Treatment
-----------------
* Behavioral: Appointment reminders, motivational interviewing and targeted vaccine drives


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All parents or caregivers of patients who bring their child to the vaccine clinic to receive immunization for their first vaccine visit. Exclusion Criteria: Parents or caregivers not willing to participate.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Intervention Model: Single Group Assignment
Interventional Model Description: Cohort study
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intervention<br>Prospectively received appointment reminders, motivational interviews and targeted vaccine drives. | Behavioral: Appointment reminders, motivational interviewing and targeted vaccine drives<br>* Automated and real time phone call reminders, motivational interviewing and targeted vaccine drives applied in sequence<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vaccine completion rates | Receipt of all routine childhood vaccines | 15 Months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Vaccination, Childhood, Low- and middle-income country
Choroidal Thickness Vitrectomy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the influence of vitrectomy on changes in central choroidea and comparing the results in imaging of the choroidea with two different OCT devices. This is a prospective, open, non-randomized, observational, MPG study This study will be performed at the Department of Ophthalmology, Medical University of Vienna. 40 Patients who undergo vitrectomy will be included into this study. The investigation will help to gain new information about the effects of vitrectomy on the choroid.

Detailed Description
-----------------
Since the development of new OCT modalities, like enhanced depth or swept-source OCT imaging, a better visualization and evaluation of retinal structures and the choroidea became possible. 23G Vitrectomy and membrane peeling seem to have an influence on posterior segment structures of the eye but data show no clear evidence evaluating those changes after surgery. Only little information is currently available on the influence or the changes resulting from vitreous surgery on the central choroidea. Hence, the aim of this study is to evaluate those influences resulting on choroidea using two different OCT devices. To assess the influence of vitrectomy on changes in central choroidea and comparing the results in imaging of the choroidea with two different OCT devices. This is a prospective, open, non-randomized, observational, MPG study This study will be performed at the Department of Ophthalmology, Medical University of Vienna. 40 Patients who undergo vitrectomy will be included into this study. The investigation will help to gain new information about the effects of vitrectomy on the choroid. The measuring procedures used in this study are well tolerated and used in routine clinical practice and are non-invasive.

Official Title
-----------------
Influence of Vitrectomy and Membrane Peeling on Choroidal Thickness

Conditions
-----------------
Epiretinal Membrane

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with epiretinal membrane scheduled to undergo vitrectomy without endotamponade Male or female, at least 18 years of age Written informed consent has been obtained Visual acuity ≥0.4 Exclusion Criteria: Any abnormalities preventing reliable measurements as judged by the investigator Participation in a clinical trial in the 3 weeks preceding the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| choroidal thickness using 2 different OCT devices |  | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual Acuity using Snellen charts |  | 3 months |
A Study of Ibandronate [Bonviva/Boniva] and Alendronate in Female Patients With Post-Menopausal Osteoporosis

Study Overview
=================
Brief Summary
-----------------
This observational study will assess the compliance and persistence of patients, real life efficacy and safety of intravenously quarterly administered 3 mg ibandronate [Bonviva/Boniva] in comparison to oral alendronate generics in female patients with post-menopausal osteoporosis. The anticipated time of assessment is 12 months. The target sample size is 5000-7000 patients.

Official Title
-----------------
Controllability and Real Life Efficacy of Bonviva 3 mg iv Quarterly vs. Oral Alendronate Generics

Conditions
-----------------
Postmenopausal Osteoporosis

Intervention / Treatment
-----------------
* Drug: alendronate
* Drug: ibandronate [Bonviva/Boniva]


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients, >/= 55 years of age Postmenopausal osteoporosis Patients who are in the opinion of the physician eligible to participate in this study Exclusion Criteria: N/A

Ages Eligible for Study
-----------------
Minimum Age: 55 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br> | Drug: ibandronate [Bonviva/Boniva]<br>* As prescribed by physician<br>|
| 2<br> | Drug: alendronate<br>* As prescribed by physician<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of compliance and persistence of Bonviva therapy: Number of prescriptions, number of applied injections, number of taken oral medication, continuation and duration of treatment |  | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain intensity and reduction in use of analgesics |  | 12 months | 
| Quality of life and patients satisfaction |  | 12 months | 
| Degree of patient's mobility |  | 12 months | 
| Incidence of new osteoporotic fractures |  | 12 months | 
| Controllability and management of therapy by the physician |  | 12 months | 
| Patient baseline characteristics |  | 12 months | 
| User friendliness |  | 12 months | 
| Safety: AEs and SAEs |  | 12 months |
Clinical Experience With the Hindfoot Arthrodesis Nail for the Surgical Treatment of Ankle and Hindfoot Pathologies

Study Overview
=================
Brief Summary
-----------------
The aim of this observational study is to collect and evaluate the current clinical experience gained from the Hindfoot Arthrodesis Nail (HAN) for ankle and hindfoot fusions.

Detailed Description
-----------------
The HAN (Synthes) is a newly designed, titanium nail for trans-calcaneal, retrograde hindfoot fusion. The lateral bend allows an entry site in the center of the lateral column of the calcaneus, thus minimizing the risk of iatrogenic injury of the plantar neurovascular bundle.

Official Title
-----------------
Clinical Experience With the Hindfoot Arthrodesis Nail (HAN) for the Surgical Treatment of Ankle and Hindfoot Pathologies. A Retrospective Case Series.

Conditions
-----------------
Hindfoot Arthrodesis, Hindfoot Pathologies

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: HAN fusion procedure ≥ 12 months before entering the study. Written or oral informed consent.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The aim of this observational study is to collect and evaluate the current clinical experience gained from the Hindfoot Arthrodesis Nail (HAN) for ankle and hindfoot fusions. |  | More than 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Technical and surgical details Patient-centered endpoints (e.g., function as assessed by AAOS Foot and Ankle Outcomes Questionnaire (AAOS-FAOQ) score and the SF-36 Health Survey) |  | More than 1 year |
Study Evaluating MOA-728 in Subjects on Stable Methadone Maintenance

Study Overview
=================
Brief Summary
-----------------
This is a study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MOA-728 in subjects on stable methadone maintenance.

Official Title
-----------------
Two Ascending Single Doses Crossover, Placebo Controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MOA-728 Administered Orally to Subjects on Stable Methadone Maintenance

Conditions
-----------------
Methadone-maintenance Subjects

Intervention / Treatment
-----------------
* Drug: MOA-728


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: History of methadone treatment for at least 1 month before day -1 at a dose of ≥ 30 mg/day, and a positive drug test result for methadone. Healthy as determined by the investigator on the basis of screening evaluations. Exclusion Criteria: Allergy to opioids (eg, codeine, morphine, or oxymorphone) or opioid antagonists (eg, naloxone or naltrexone). Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: MOA-728|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pharmacokinetics |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety, tolerability, and pharmacodynamics |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Methadone